Construction of eukaryotic expression vector for recombinant vascular endothelial growth factor for coating interventional device

doi:10.3877/cma.j.issn.2095-5782.2019.01.008

Abstract

Abstract:

Objective:

To construct the eukaryotic expression vector for recombinant vascular endothelial growth factor (VEGF) for coating interventional device.

Methods:

The primer was designed to prepare the target gene and vector according to the sequence of human VEGFA (NM_001025366) , and then was connected and transformed to E. coli after double digestion of homo VEGFA and pIRES2-ZsGreen1 plasmids. Then the vector pIRES2-ZsGreen1-homo-VEGFA was constructed and identified.

Results:

The target gene, VEGFA, has been connected to the vector pIRES2-ZsGreen1, which was a 1400 bp plasmid. The sequence alignment was consistent with that of human VEGFA (NM_001025366) and no mutation was found. Plasmid pIRES2-ZsGreen1-homo-VEGFA was successfully constructed.

Conclusions:

The eukaryotic expression vector pIRES2-ZsGreen1-homo-VEGFA is successfully constructed, and can be used to coat interventional device.

Key words: Vascular endothelial growth factor, Interventional device, Plasmid, Gene

Yilin Zhang, Yingkun He, Tianxiao Li, Gang Liu, Yanzhong Hu, Xiukun Cui. Construction of eukaryotic expression vector for recombinant vascular endothelial growth factor for coating interventional device[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2019, 07(01): 40-43.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2019.01.008

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2019/V07/I01/40

Figures/Tables 3

References 18

[1]	Lutsep HL. Symptomatic intracranial stenosis: best medical treatment vs. intracranial stenting[J]. Curr Opin Neurol，2009，22(1):69-74.
[2]	Chimowitz MI, Lynn MJ, Derdeyn CP，et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis[J]. N Engl J Med，2011，365(11):993-1003.
[3]	Jin M, Fu X, Wei Y，et al. Higher risk of recurrent ischemic events in patients with intracranial in-stent restenosis[J]. Stroke，2013，44(11):2990-2994.
[4]	Zhu SG, Zhang RL, Liu WH，et al. Predictive factors for in-stent restenosis after balloon-mounted stent placement for symptomatic intracranial atherosclerosis [J]. Eur J Vasc Endovasc Surg，2010，40(4):499-506.
[5]	Bach LA. Endothelial cells and the IGF system[J]. J Mol Endocrinol，2015，54(1):1-13.
[6]	饶璇，李元建.内皮细胞损伤与修复的研究进展[J].中国动脉硬化杂志，2017，25(5):531-535.
[7]	Gimbrone MA Jr, García-Cardena G. Endothelial cell dysfunction and the pathobiology of atherosclerosis [J]. Circ Res，2016，118(4):620-636.
[8]	Josko J, Gwózdz B, Jedrzejowska-Szypulka H，et al. Vascular endothelial growth factor（VEGF）and its effect on angiogenesis [J]. Med Sci Monit，2000，6(5):1047-1052.
[9]	刘朝辉，高晓虹.血管内皮生长因子及其受体的研究进展[J].中国药物与临床，2017，17(8):1162-1164.
[10]	Achen MG, Stacker SA. The vascular endothelial growth factor family: proteins which guide the development of the vasculature[J]. Int J Exp Pathol，1998，79(5):255-265.
[11]	Isner JM, Pieczek A, Schainfeld R，et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb [J]. Lancet，1996，348(9024):370-374.
[12]	贺迎坤，李天晓，白卫星，等.脑血管药物洗脱支架与金属裸支架治疗椎动脉狭窄的临床随机对照研究方案[J].中华介入放射学电子杂志，2016，4(2):109-114.
[13]	Robertson KE, McDonald RA, Oldroyd KG，et al. Prevention of coronary in-stent restenosis and vein graft failure: does vascular gene therapy have a role? [J]. Pharmacol Ther，2012，136(1):23-34.
[14]	Banai S, Jaklitsch MT, Shou M，et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs [J]. Circulation，1994，89(5):2183-2189.
[15]	Hendel RC, Henry TD, Rocha-Singh K，et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion evidence for a dose-dependent effect [J]. Circulation，2000，101(2):118-121.
[16]	陈良万，郭加强.外源性基因在在体血管壁中表达的实验研究[J].中华心血管病杂志，1995，23(4):294-295.
[17]	黄志雄，郭加强，李晓惠，等.可溶性支架转移基因的实验研究[J].中华外科杂志，1997，35(5):310-312.
[18]	Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? [J]. Nat Med，2000，6(10):1102-1103.

Please choose a citation manager

Content to export